Investor Overview

Investor Presentation
Financial News
Jan 13, 2020

Survival improvement of over 150% seen in MDNA55 subjects compared to a Synthetic Control Arm TORONTO and HOUSTON, Jan 13, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company")...

Jan 8, 2020

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received $1,345,871 from the early...

Stock Quote
TSXMDNA
Stock Chart
TSXMDNA
Upcoming Events
No events to display
Investor Contact
For more investor information, Please contact:
 
Elizabeth Williams, Chief Financial Officer
 
 
Email Alerts
* Required Fields